Recent Stock Performance: Amgen Inc. has been a focal point of discussion on social media due to its stock price movements in 2025. A recent dip followed by a strong rally has sparked debates about the sustainability of its upward trend. Some users see the fluctuations as a potential entry point, while others express caution.
Revenue Guidance and Drug Sales: The conversation has also centered on Amgen’s updated 2025 revenue guidance, driven by robust sales of key drugs like Repatha and Imdelltra. Social media buzz highlights optimism around these developments, alongside news of a dividend hike. There’s also chatter about a recent credit rating upgrade, adding to the positive momentum.
Drug Pricing Deal: A reported drug pricing deal linked to political developments has caught attention on social media platforms. Users are split on how this might impact Amgen’s long-term profitability and stock trajectory. The mix of speculation and analysis keeps the dialogue engaging and dynamic.
Note: This discussion summary was generated from an AI condensation of post data.
Amgen Inc. Insider Trading Activity
Amgen Inc. insiders have traded $AMGN stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $AMGN stock by insiders over the last 6 months:
- MURDO GORDON (EVP, Global Commercial Ops) sold 6,879 shares for an estimated $2,317,071
- NANCY A. GRYGIEL (SVP & CCO) has made 0 purchases and 3 sales selling 4,406 shares for an estimated $1,434,946.
- RACHNA KHOSLA (SVP, Business Development) sold 890 shares for an estimated $299,255
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Amgen Inc. Revenue
Amgen Inc. had revenues of $9.6B in Q3 2025. This is an increase of 12.4% from the same period in the prior year.
You can track AMGN financials on Quiver Quantitative's AMGN stock page.
Amgen Inc. Congressional Stock Trading
Members of Congress have traded $AMGN stock 6 times in the past 6 months. Of those trades, 2 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $AMGN stock by members of Congress over the last 6 months:
- REPRESENTATIVE DAVID TAYLOR has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/03.
- REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 2 times. They made 2 purchases worth up to $30,000 on 10/24, 09/11 and 0 sales.
- REPRESENTATIVE LISA C. MCCLAIN sold up to $15,000 on 09/25.
- SENATOR SHELDON WHITEHOUSE sold up to $15,000 on 09/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Amgen Inc. Hedge Fund Activity
We have seen 1,250 institutional investors add shares of Amgen Inc. stock to their portfolio, and 1,443 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 3,816,157 shares (+72.2%) to their portfolio in Q3 2025, for an estimated $1,076,919,505
- CAPITAL WORLD INVESTORS added 1,935,876 shares (+11.5%) to their portfolio in Q3 2025, for an estimated $546,304,207
- PRIMECAP MANAGEMENT CO/CA/ removed 924,100 shares (-8.7%) from their portfolio in Q3 2025, for an estimated $260,781,020
- NATIONAL BANK OF CANADA /FI/ added 866,166 shares (+240.5%) to their portfolio in Q3 2025, for an estimated $244,432,045
- MONTRUSCO BOLTON INVESTMENTS INC. removed 689,602 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $192,543,774
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 656,935 shares (+5.1%) to their portfolio in Q3 2025, for an estimated $185,387,057
- PERRITT CAPITAL MANAGEMENT INC removed 599,055 shares (-99.6%) from their portfolio in Q3 2025, for an estimated $169,053,321
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Amgen Inc. Analyst Ratings
Wall Street analysts have issued reports on $AMGN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- BMO Capital issued a "Outperform" rating on 12/03/2025
- Piper Sandler issued a "Overweight" rating on 11/14/2025
- B of A Securities issued a "Underperform" rating on 09/26/2025
To track analyst ratings and price targets for Amgen Inc., check out Quiver Quantitative's $AMGN forecast page.
Amgen Inc. Price Targets
Multiple analysts have issued price targets for $AMGN recently. We have seen 9 analysts offer price targets for $AMGN in the last 6 months, with a median target of $317.0.
Here are some recent targets:
- Terence Flynn from Morgan Stanley set a target price of $304.0 on 12/12/2025
- Mohit Bansal from Wells Fargo set a target price of $325.0 on 12/10/2025
- Evan David Seigerman from BMO Capital set a target price of $372.0 on 12/03/2025
- Gregory Renza from Truist Securities set a target price of $318.0 on 11/24/2025
- David Amsellem from Piper Sandler set a target price of $381.0 on 11/14/2025
- Carter Gould from Cantor Fitzgerald set a target price of $315.0 on 11/06/2025
- Tim Anderson from B of A Securities set a target price of $272.0 on 09/26/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
